抗CD45抗体药物偶联物清除并替换组织驻留髓系细胞
研究评估抗CD45抗体药物偶联物(ADC)对多种组织驻留髓系(TRM)细胞的清除与替换效果。单次抗CD45-ADC联合骨髓造血细胞移植后,肝、肺、皮肤TRM替换效率为40%至95%,脑小胶质细胞未受影响而脑单核细胞和巨噬细胞替换50%。在Tet2突变克隆性造血加重的动脉粥样硬化中,该方案替换斑块驻留髓系细胞并减少现有斑块负荷。
要点
- 单次抗CD45-ADC加骨髓造血细胞移植后,肝、肺、皮肤TRM细胞替换效率为40%至95%。
- 脑小胶质细胞未受影响,脑单核细胞和巨噬细胞替换50%。
- 在Tet2突变克隆性造血加重的动脉粥样硬化中,抗CD45-ADC联合野生型骨髓细胞替换斑块驻留髓系细胞并减少现有斑块负荷。
核心结论
- 抗CD45-ADC可清除造血干细胞和组织驻留髓系细胞,实现细胞替换,从而在驻留髓系细胞驱动的疾病中达到疾病修饰。
研究设计与样本
- 研究评估单次抗CD45-ADC剂量联合骨髓造血细胞移植对多种组织TRM细胞的影响,并在Tet2突变克隆性造血加重的慢性获得性动脉粥样硬化条件下测试抗CD45-ADC联合过继细胞移植。
主要发现
- 单次抗CD45-ADC剂量加骨髓造血细胞移植后,肝、肺、皮肤组织TRM细胞替换效率为40%至95%。
- 组织中TRM细胞群体大小恢复至治疗前水平,提示TRM细胞丰度受调控。
- 脑小胶质细胞未受影响,脑单核细胞和巨噬细胞替换50%。
- 在Tet2突变克隆性造血加重的动脉粥样硬化中,抗CD45-ADC联合野生型骨髓细胞有效替换斑块驻留髓系细胞,并减少现有动脉粥样硬化斑块负荷。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tissue-resident myeloid (TRM) cells in adults have highly variable lifespans, and may be derived from early embryonic yolk sac, fetal liver, or bone marrow. Some of these TRM cells are known pathogenic participants in congenital and acquired diseases. Myeloablative conditioning and hematopoietic stem cell transplantation can replace long-lived brain TRM cells, resulting in clinical improvements in metabolic storage diseases. With the advent of antibody-drug conjugate (ADC)-targeted cell killing as a cell-selective means of transplant conditioning, we assessed the impact of anti-CD45-ADC on TRM cells in multiple tissues. Replacement of TRM cells ranged from 40% to 95% efficiencies in liver, lung, and skin tissues, after a single anti-CD45-ADC dose and bone marrow hematopoietic cell transfer. Of note, the population size of TRM cells in tissues returned to pretreatment levels, suggesting a regulated control of TRM cell abundance. As expected, brain microglia were not affected, but brain monocytes and macrophages were 50% replaced. Anti-CD45-ADC and adoptive cell transfer were then tested in the chronic acquired condition, atherosclerosis exacerbated by Tet2 mutant clonal hematopoiesis. Plaque-resident myeloid cells were efficiently replaced with anti-CD45-ADC and wild-type bone marrow cells. Notably, this reduced existent atherosclerotic plaque burden. Overall, these results indicate that the anti-CD45-ADC clears both hematopoietic stem and TRM cells from their niches, enabling cell replacement to achieve disease modification in a resident myeloid cell-driven disease.
引用
- Gustafsson K, Rhee C, Frodermann V, et al. Clearing and replacing tissue-resident myeloid cells with an anti-CD45 antibody-drug conjugate. Blood Adv. 2023. PMID: 37748049. doi:10.1182/bloodadvances.2023010561
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。